H.R.1776

The Improving Access to Affordable Prescription Drugs Act

The summary of the act is provided by www.citizen.org. Information below is taken directly from the Section-by-Section summary provided by the organization. 

​

The act is divided into 18 sections. We've highlighted the most important pieces of the legislation.

​

Title I - Transparency

Sec. 101 Drug manufacturer reporting

Sec. 102 Determining the public and private benefit of co-payment coupons and other patient assistance programs

​

Title II - Access and Affordability

Sec.201 Negotiating fair prices for Medicare prescription drugs

Sec.202 Prescription drug price spikes

Sec.203 Acceleration of the closing of the Medicare Part D coverage gap

Sec.204 Importing affordable and safe drugs

Sec.205 Requiring drug manufacturers to provide drug rebates fro drugs dispensed to low-income individuals

Sec.206 Cap on prescription drug cost-sharing

​

Title III - Innovation

Sec.301 Prize fund for new and more effective treatments of bacterial infections

Sec.302 Public funding for clinical trials

Sec.303 Rewarding innovative drug development

Sec.304 Improving program integrity

​

Title IV - Choice and Competition

Sec.401 Preserving access to affordable generics

Sec.402 180-Day exclusivity period amendments regarding first applicant status

Sec.403 180-Day exclusivity period amendments regarding agreements to defer commercial marketing

Sec.404 Increasing generic drug competition

Sec.405 Disallowance of deduction for advertising for prescription drugs

Sec.406 Product Hopping

​

Each week in October we will highlight a Title of the bill and share editorials and other information with you. Check back for more information.

Week of:

• October 1: Title II - Access and Affordability

• October 8: Title III - Innovation

• October 15: Title IV - Choice and Competition

• October 22: Title I - Transparency